New
Image

14.08.2025
Groundbreaking immunotherapy drug teplizumab licensed in UK for delayi...
The first-ever immunotherapy for type 1 diabetes has been licensed for use in the UK. The Medicines and H...
customer support
customer support
We take a look at some of the exciting diabetes research developments announced in July, including how teplizumab targets type 1 diabetes and understanding the risk of eating disorders for people taking part in type 2 diabetes remission programmes.
Read more